E3612: A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
Aims: The purpose of this research study is to compare the good and bad effects of using the study drug called ipilimumab either alone or in combination with the study drug called bevacizumab. This regimen could help improve how long you are able to live with your cancer, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach used to treat advanced melanoma. Ipilimumab is approved by the FDA at a dose of 3 mg/kg for a total of 4 doses given 3 weeks apart for metastatic melanoma that cannot all be removed or treated with surgery. Bevacizumab is not approved by the FDA to treat melanoma, and is an investigational treatment. There will be about 168 people taking part in this study. Ten of those patients will be from NorthShore University HealthSystem.
Diagnosis: Unresectable Stage III or Stage IV Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH14-171
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes